Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone
出版年份 2016 全文链接
标题
Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone
作者
关键词
Hypoglycemia, Glycemic Control, Fast Plasma Glucose, Liraglutide, Basal Insulin
出版物
CLINICAL DRUG INVESTIGATION
Volume 36, Issue 4, Pages 293-303
出版商
Springer Nature
发表日期
2016-02-19
DOI
10.1007/s40261-016-0376-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial
- (2015) S. C. L. Gough et al. DIABETES OBESITY & METABOLISM
- Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes
- (2015) H. W. Rodbard et al. DIABETES OBESITY & METABOLISM
- A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
- (2014) Hanne Haahr et al. CLINICAL PHARMACOKINETICS
- Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
- (2014) Julio Rosenstock et al. DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
- (2014) John B. Buse et al. DIABETES CARE
- Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
- (2014) Michaela Diamant et al. DIABETES CARE
- A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)
- (2014) C. Mathieu et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis
- (2014) Conrad Eng et al. LANCET
- Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
- (2014) Stephen C L Gough et al. Lancet Diabetes & Endocrinology
- Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes
- (2013) John B. Buse et al. ANNALS OF INTERNAL MEDICINE
- Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people
- (2013) K. Khunti et al. DIABETES CARE
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin
- (2013) Matthew C. Riddle et al. DIABETES CARE
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine
- (2013) Matthew C. Riddle et al. DIABETES CARE
- Incretin-based therapy in combination with basal insulin: A promising tactic for the treatment of type 2 diabetes
- (2012) J. Vora et al. DIABETES & METABOLISM
- Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets
- (2012) J. H. DeVries et al. DIABETES CARE
- Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
- (2012) B. Zinman et al. DIABETES CARE
- Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
- (2012) Y. Seino et al. DIABETES OBESITY & METABOLISM
- A retrospective database study of insulin initiation in patients with Type 2 diabetes in UK primary care
- (2012) B. T. Blak et al. DIABETIC MEDICINE
- Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study
- (2012) M. Peyrot et al. DIABETIC MEDICINE
- Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review
- (2012) Johan Jendle et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The Effect of Liraglutide Added to U-500 Insulin in Patients with Type 2 Diabetes and High Insulin Requirements
- (2011) Wendy Lane et al. Diabetes Technology & Therapeutics
- Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction
- (2011) Marcus Lind et al. Primary Care Diabetes
- Addressing barriers to initiation of insulin in patients with type 2 diabetes
- (2010) Mark Peyrot et al. Primary Care Diabetes
- Exenatide added to insulin therapy: A retrospective review of clinical practice over two years in an academic endocrinology outpatient setting
- (2009) Nancy M. Yoon et al. CLINICAL THERAPEUTICS
- How Does Treatment Satisfaction Work?: Modeling determinants of treatment satisfaction and preference
- (2009) M. Peyrot et al. DIABETES CARE
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Psychological insulin resistance: patient beliefs and implications for diabetes management
- (2008) Meryl Brod et al. QUALITY OF LIFE RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started